NCT00056550View on ClinicalTrials.gov

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

PHASE3CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

February 29, 2004

Study Completion Date

February 29, 2004

Conditions
Antithrombin Deficiency, Congenital
Interventions
BIOLOGICAL

Recombinant Human Antithrombin (rhAT)

Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.

Trial Locations (11)

Unknown

Marietta

Charleston

Paris

Toulouse

Berlin

Hanover

Mannheim

Milan

Stockholm

Bristol

Manchester

Sponsors

Lead Sponsor

rEVO Biologics
All Listed Sponsors
lead

rEVO Biologics

INDUSTRY

NCT00056550 - Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations. | Biotech Hunter | Biotech Hunter